Peptides A to Z

How the profiles are built

Each profile condenses the peptide science on one compound. It opens with a short answer to what the compound is and a key facts table: class, other names, the forms the store sells (or "not sold here"), regulatory status and anti-doping status. Sections follow on what sources report, side effects, dosage information, storage and regulation. Profiles of approved medicines follow the FDA label. Profiles of research compounds give only doses used in published studies, with species, route and duration, and say when no human dose is established. Where a compound has more to cover, separate pages on side effects, dosage, benefits or reconstitution sit under its profile.

Brand-name medicines and their active ingredients have separate profiles that link to each other. The directory above lists every profile from A to Z; the groups below sort the same profiles by research area.

Profiles by research area

GLP-1 medicines and related compounds

Semaglutide is the active ingredient in Ozempic (approved by FDA in 2017), Rybelsus (2019) and Wegovy (2021), and tirzepatide is the active ingredient in Mounjaro (2022) and Zepbound (2023).¹ Retatrutide, by contrast, is not a component of any FDA-approved drug and cannot be used in compounding under federal law, FDA says.⁹ Profiles: semaglutide, Ozempic, Wegovy, Rybelsus, tirzepatide, Mounjaro, Zepbound and retatrutide. The GLP-1 hub explains the class as a whole.

Growth hormone axis

CJC-1295 is a modified copy of the first 29 amino acids of growth hormone-releasing hormone (GHRH), which acts on GHRH receptors in the anterior pituitary, prompting it to release growth hormone (GH); GH in turn raises IGF-1.⁴ Ipamorelin also triggers GH release, but through a different receptor: the ghrelin receptor (GHSR-1a).¹⁰ Somatropin (HGH) products replace GH directly and are FDA-approved for GH deficiency.²⁴ Tesamorelin is approved as EGRIFTA SV to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.³ Sermorelin, the unmodified GHRH(1-29) chain, was FDA-approved as Geref for short stature caused by GH deficiency in children, while no form of CJC-1295 has been approved.¹¹²⁴ FDA lists GHRP-2, GHRP-6 and mechano growth factor (MGF) in 503A Category 3, meaning they were nominated for compounding without adequate support.¹²

Profiles: HGH, sermorelin, tesamorelin, CJC-1295 with DAC, CJC-1295 without DAC, CJC-1295 + Ipamorelin, ipamorelin, GHRP-2, GHRP-6, IGF-1, MGF, HGH Fragment 176-191 and AOD-9604.

Tissue repair and inflammation research

In July 2026, FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, and TB-500 for wound healing, as candidates for the list of bulk substances pharmacies may compound.¹³ FDA says it has not identified human exposure data for TB-500 or for products containing KPV.¹⁴ GHK-Cu is split by route: FDA is still evaluating it for non-injectable use, while for injectable GHK-Cu it cites a risk of immune reactions and limited human data.¹²¹⁴ FDA calls the safety information on thymosin alpha-1 inadequate, and lists ARA-290 (cibinetide) in Category 3.¹⁴¹²

Profiles: BPC-157, TB-500, KPV, GHK-Cu, thymosin alpha-1, ARA-290, Wolverine Stack, Glow Peptide Stack and KLOW Peptide Blend. The blends and stacks hub shows what each of the three blends holds.

Tanning and sexual health

FDA cites published case reports of serious adverse events with melanotan II, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.¹⁴ Bremelanotide is FDA-approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder.¹⁹ Separately, in an August 2026 warning letter, FDA named a seller's PT-141 (bremelanotide) product among the unapproved new drugs it found.¹⁵ Profiles: Melanotan 2, PT-141 and Vyleesi.

Reproductive health

Kisspeptin-10 is on FDA's current 503A Category 2 list, the bulk substances that raise significant safety concerns.¹² FDA cites a risk of immune reactions, impurity and characterization problems, and limited safety information.¹⁴ In a June 2026 warning letter, FDA named a seller's gonadorelin as an unapproved new drug, quoting product text framed as research on testosterone production.¹⁶ For male athletes, WADA's 2026 list prohibits gonadorelin and kisspeptin at all times.¹⁷ Profiles: kisspeptin-10, HCG, HMG and gonadorelin.

MOTS-c, SS-31 and NAD+

FDA says it has not identified human exposure data on drug products containing MOTS-c, and its advisory committee discussed MOTS-c for obesity and osteoporosis in July 2026.¹⁴¹³ Elamipretide, also called SS-31, received FDA accelerated approval as Forzinity in September 2025 to treat Barth syndrome in patients weighing at least 30 kg.¹⁸ The August 2026 warning letter still named a seller's SS-31 (elamipretide) product as an unapproved new drug.¹⁵ NAD (nicotinamide adenine dinucleotide) is in 503A Category 1, which means FDA is still evaluating it.¹² Profiles: MOTS-c, SS-31 and NAD+.

Brain and sleep research

FDA's advisory committee discussed three peptides in this area in July 2026: emideltide (DSIP) for opioid withdrawal, chronic insomnia and narcolepsy; semax for cerebral ischemia, migraine and trigeminal neuralgia; and epitalon for insomnia.¹³ For selank, semax, epitalon and DSIP alike, FDA says it lacks the safety information it would need to judge their risks in people.¹⁴ Profiles: DSIP, semax, selank, Epithalon and Pinealon.

Other research peptides

Six more research peptides have profiles: Cardiogen, Cartalax, Cortagen, Livagen, Testagen and Vilon. Each profile reports what published sources say about the compound and names the evidence level.

Where to go next

The Learn section explains what peptides are and how this site grades evidence. The research peptides page covers research labeling and certificates of analysis, and the store's peptide shop lists every compound it sells.